{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:43:44Z","timestamp":1791960224539,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1038\/eye.2000.83","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T09:19:15Z","timestamp":1309771155000},"page":"334-339","source":"Crossref","is-referenced-by-count":28,"title":["Vigabatrin-associated visual field defects in children"],"prefix":"10.1038","volume":"14","author":[{"given":"I M","family":"Russell-Eggitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D S I","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Timms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFeye200083_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1177\/0883073897012001031","volume":"12","author":"DA Coulter","year":"1997","unstructured":"Coulter DA . Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl 1):S2\u20139.","journal-title":"J Child Neurol"},{"key":"BFeye200083_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199717040-00003","volume":"17","author":"S Natsch","year":"1997","unstructured":"Natsch S, Hekster YA, Keyser A, Deckers CL, Meinardi H, Renier WO . Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Safety 1997;17:228\u201340.","journal-title":"Drug Safety"},{"key":"BFeye200083_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(97)05035-6","volume":"351","author":"PJ Leach","year":"1998","unstructured":"Leach PJ, Brodie MJ . Tiagabine. Lancet 1998;351:203\u20137.","journal-title":"Lancet"},{"key":"BFeye200083_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/019262339001800201","volume":"18","author":"JP Gibson","year":"1990","unstructured":"Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies with vigabatin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225\u201338.","journal-title":"Toxicol Pathol"},{"key":"BFeye200083_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/bmj.316.7126.232","volume":"316","author":"GF Harding","year":"1998","unstructured":"Harding GF . Severe persistent visual field constriction associated with vigabatrin. Benefit:risk ratio must be calculated for individual patients. BMJ 1998;316:232\u20133.","journal-title":"BMJ"},{"key":"BFeye200083_CR6","first-page":"S30","volume":"33","author":"EH Reynolds","year":"1992","unstructured":"Reynolds EH . Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy. Epilepsia 1992;33(Suppl 5);S30\u20134; discussion S34\u20135.","journal-title":"Epilepsia"},{"key":"BFeye200083_CR7","first-page":"105","volume":"15","author":"MT Faedda","year":"1993","unstructured":"Faedda MT, Giallonardo AT, Marchetti A, Manfredi M . Terepia con vigabatrin nelle epilessie parziali resistenti. (Vigabatrin therapy for resistant partial epilepsies.) G Neuropsicofarmacol 1993;15:105\u20138.","journal-title":"G Neuropsicofarmacol"},{"key":"BFeye200083_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC . Severe persistent visual field constriction associated with Vigabatrin. BMJ 1997;314:180\u20131.","journal-title":"BMJ"},{"key":"BFeye200083_CR9","unstructured":"Anon. Does vigabatrin affect the eye? Pharm J 1997;258:120."},{"key":"BFeye200083_CR10","first-page":"233","volume":"31","author":"R Mackenzie","year":"1998","unstructured":"Mackenzie R, Klistorner A . Severe persistent visual field constriction associated with Vigabatrin: asymptomatic as well as symptomatic defects occur with Vigabatrin [letter]. BMJ 1998;31:233.","journal-title":"BMJ"},{"key":"BFeye200083_CR11","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","volume":"314","author":"EA Wilson","year":"1997","unstructured":"Wilson EA, Brodie MJ . Severe persistent visual field constriction associated with Vigabatrin. Chronic refractory epilepsy may have a role in causing these unusual lesions. BMJ 1997;314:1693.","journal-title":"BMJ"},{"key":"BFeye200083_CR12","first-page":"1694","volume":"314","author":"N Blackwell","year":"1997","unstructured":"Blackwell N, Hayllar J, Kelly G . Severe persistent visual field constriction associated with Vigabatrin: patients taking Vigabatrin should have regular VF examination. BMJ 1997;314:1694.","journal-title":"BMJ"},{"key":"BFeye200083_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0013-4694(97)88397-X","volume":"103","author":"G Harding","year":"1997","unstructured":"Harding G, Wild J, Robertson K, Edson E, Barber C, Lawden M, et al. Electrooculography, EOGs, multi-focal ERGs and VEPs in epileptic patients showing visual field disorders. Electroencephalogr Clin Neurophysiol 1997;103:96.","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"BFeye200083_CR14","first-page":"1693","volume":"314","author":"IC Wong","year":"1997","unstructured":"Wong IC, Mawer GE, Sander JW . Severe persistent visual field constriction associated with Vigabatrin: reaction may be dose dependent [letter; comment]. BMJ 1997;314:1693\u20134.","journal-title":"BMJ"},{"key":"BFeye200083_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1212\/WNL.50.3.614","volume":"50","author":"GL Krauss","year":"1998","unstructured":"Krauss GL, Johnson MA, Miller NR . Vigabatrin associated retinal cone system dysfunction: electroretinographic and ophthalmological findings. Neurology 1998;50:614\u20138.","journal-title":"Neurology"},{"key":"BFeye200083_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/bmj.317.7152.206","volume":"317","author":"GP Rao","year":"1998","unstructured":"Rao GP, Fat FA, Kyle G, Leach JP, et al. Study is needed of visual field defects associated with any long term antiepileptic drug [letter]. BMJ 1998;317:206.","journal-title":"BMJ"},{"key":"BFeye200083_CR17","first-page":"817","volume":"116","author":"K Ruether","year":"1998","unstructured":"Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field constriction associated with Vigabatrin [letter]. Arch Ophthalmol 1998;116:817\u20139.","journal-title":"Arch Ophthalmol"},{"key":"BFeye200083_CR18","unstructured":"Acheson JF, Wearne MJ, Graham EM, Sanders MD . Vigabatrin-associated visual failure: analysis of 4 cases presenting with major visual field defects. Poster presentation at the Oxford Congress of Ophthalmology, 1999."},{"key":"BFeye200083_CR19","first-page":"S63","volume":"40","author":"DA Mackey","year":"1999","unstructured":"Mackey DA, Craig JE, Gioulekas J, Cooper RL . Vigabatrin associated visual field loss resembling low tension glaucoma. Invest Ophthalmol Vis Sci 1999;40:S63\u2013339.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye200083_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0140-6736(99)02095-4","volume":"354","author":"M Versino","year":"1999","unstructured":"Versino M, Veggiotti P . Reversibility of vigabatrin-induced visual-field defect. Lancet 1999;354:486.","journal-title":"Lancet"},{"key":"BFeye200083_CR21","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","volume":"106","author":"H Daneshvar","year":"1999","unstructured":"Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A . Symptomatic and asymptomatic visual loss in patients taking Vigabatrin. Ophthalmology 1999;106:1792\u20138.","journal-title":"Ophthalmology"},{"key":"BFeye200083_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/bmj.319.7218.1165","volume":"139","author":"LV Wilton","year":"1999","unstructured":"Wilton LV, Stephens MDB, Mann RD . Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999;139:1165\u20136.","journal-title":"BMJ"},{"key":"BFeye200083_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1212\/WNL.51.6.1779-a","volume":"51","author":"A Roubertie","year":"1998","unstructured":"Roubertie A, Bellet H, Echenne B . Vigabatrin-associated retinal cone system dysfunction [letter; comment]. Neurology 1998;51:1779\u201381.","journal-title":"Neurology"},{"key":"BFeye200083_CR24","unstructured":"Beren R, Currie J, Sandbach J, Plunkett M . Visual field restriction with new anti-epileptic medications [abstract]. European Epilepsy Society, Warsaw, May 1998."},{"key":"BFeye200083_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0140-6736(05)79254-0","volume":"352","author":"M Baulac","year":"1998","unstructured":"Baulac M, Nordmann J-P, Lanoe Y. Severe visual-field constriction and side effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.","journal-title":"Lancet"},{"key":"BFeye200083_CR26","first-page":"P03.118","volume":"52","author":"R Kalvianen","year":"1999","unstructured":"Kalvianen R, Nousiainen I, Mantyjarvi M, Riekkinen Sr PPJ . Absence of concentric visual fields in patients with long-term Tiagabine monotherapy. Neurology 1999;52(Suppl 2):P03.118.","journal-title":"Neurology"},{"key":"BFeye200083_CR27","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/bmj.314.7087.1130","volume":"314","author":"GFA Harding","year":"1997","unstructured":"Harding GFA . Severe persistent visual field constriction associated with Vigabatrin: four possible explanations exist [letter, comment]. BMJ 1997;314:1694.","journal-title":"BMJ"},{"key":"BFeye200083_CR28","unstructured":"Hoechst Marion Roussel Australia. Guidelines for clinical practise. Visual field constriction and Vigabatrin (Sabril) 1998."},{"key":"BFeye200083_CR29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/bmj.317.7168.1322","volume":"317","author":"RE Appleton","year":"1998","unstructured":"Appleton RE . Guidelines may help in prescribing vigabatrin. BMJ 1998;317:1322.","journal-title":"BMJ"},{"key":"BFeye200083_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/bmj.318.7175.56a","volume":"318","author":"JP Osborne","year":"1999","unstructured":"Osborne JP, Edwards SW, Hancock E, Lux AL, O'Callaghan F, Johnson T, et al. Infantile spasms and vigabatrin: study will compare effects of drugs [letter]. BMJ 1999;318:56\u20137.","journal-title":"BMJ"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye200083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye200083","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye200083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T16:59:56Z","timestamp":1684429196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye200083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["BFeye200083"],"URL":"https:\/\/doi.org\/10.1038\/eye.2000.83","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}